Breast Interventional Systems

Audience: breast center directors, interventional radiology leads, pathology stakeholders, and procurement teams building or expanding imaging-guided biopsy capacity. This overview supports professional evaluation — not a substitute for IFU, credentialing pathways, or multidisciplinary tumor-board protocols.

Breast interventional programs must balance specimen adequacy (single-pass yield vs multi-pass core), imaging modality coverage, operator training burden, and replenishment logistics. Sites differ: tertiary cancer centers may invest in a dedicated VAB console ecosystem, while community hospitals often extend existing ultrasound tables with high-quality disposable needles.

Many health systems run both: integrated system in the dedicated breast suite, PickSuck needles on shared ultrasound carts at satellite sites. See integrated vs standalone guide and PickSuck vs typical VAB systems.

• Specimen adequacy — Align gauge, vacuum profile, and number of passes with pathology department standards for B5/A1 reporting turnaround.
• Single-patient use — Enforce disposable rules and traceability per hospital infection-control policy.
• Labeling & language — BBT highlights bilingual labeling where applicable for domestic tenders; verify carton labels for import markets.
• Credentialing — IR and breast surgeon privileging should reference manufacturer training where available.
• Evidence boundary — Marketing summaries do not replace peer-reviewed VAB outcomes or local screening-program guidelines.

• Annual biopsy volume by site (main campus vs satellites).
• Imaging vendor footprint (US brand, stereotactic table, MRI conditional needs).
• 3-year cost model: capital + consumables + service contracts vs needle-only spend.
• Pathology feedback loop for inadequate samples after go-live.
• Registration certificates and distributor lead times for tender scoring.